Clinical trial NCT03682224
Conditions: Non Small Cell Lung Cancer Lung Cancer Stage 1
Keywords: clinical trial bupivacaine-epinephrine bupivacaine liposome pain Morphine equivalent dose lobectomy Laproscopic lobectomy VATS lobectomy opioid medications
Sponsor: Southern Illinois University
Start date: 2018-07-05; Completion date: 2022-09-03
Enrollment: 57 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
The purpose of this study is to assess pain management after elective thoracoscopic lobectomy. The study will compare two local anesthetics that are given intra-operatively during lobectomy to see which one helps in better pain control and to see which one helps decrease the need for opioid medications. Participants will receive either Marcaine (Bupivacaine-epinephrine 0.25%, 1:200,000) or Exparel (Bupivacaine liposomal (1.3%)) and the drug will be chosen in a random fashion. Participants will be followed during the hospital stay and for one year thereafter. An visual Scale will be administered to measure pain, and opioid drug use will be measured by calculating morphine equivalent dose on each day post surgery until discharge and thereafter on 30 day, 6 month and 12 month follow-up visits. Participants will be monitored for any drug related toxicity and other co-morbid conditions for a period on one year post surgery. Overall cost for the surgery and during in hospital stay post surgery will be collected and compared between the two treatment arms.

Detailed description:
The hypothesis of this study is the possibility of liposomal bupivacaine providing more relief with less need of narcotics when compared to standard bupivacaine. To test the hypothesis the investigators will compare pain management following local infiltration of liposomal bupivacaine (Exparel®) versus standard bupivacaine HCl with epinephrine (Marcaine®) after VATS (video-assisted thoracoscopic surgery)-lobectomy. This will be accomplished by evaluating total opioid usage and patient reported pain scores.

Study will be conducted at Southern Illinois University-Medicine Clinics and Memorial Medical Center. This is a prospective, randomized, single-blind, active control trial for patients undergoing elective lobectomy. Participants will be randomly assigned to receive either Liposomal Bupivacaine 1.3% or Bupivacaine-Epinephrine 0.25%, 1:200,000 during surgery. Pain management will be monitored via opioid usage and visual pain assessment throughout the hospital stay and at postoperative day 30, 6 month and 1 year follow up visits. Study population includes patients undergoing elective standard of care lobectomy. Based on the power analysis, 150 participants (75 in each randomized group) are required to be enrolled in the study. Taking into consideration a potential loss of 50 participants due to withdrawal, lost to follow up or other reasons, 200 participants will initially be enrolled and randomized to attain 150 participants at the end of study (1-year follow up).

All patients scheduled for surgical consult with Cardiothoracic Surgery for possible video assisted thoracoscopic lobectomy will be screened for initial eligibility criteria. Informed consent form will be discussed in detail at the clinic by authorized study personnel with all participants who are willing to participate in the study. Participants will be given time to review the informed consent with family if so desired. After the participant voluntarily agrees to participate and signs the informed consent form, the inclusion/exclusion criteria will be reviewed again to ensure continued eligibility. Study data including vitals, physical examination, medications, and medical and surgical history will be recorded or obtained from the electronic health records. Participants will be randomly assigned to one of two study drugs- Liposomal Bupivacaine 1.3% or Bupivacaine-Epinephrine 0.25%, 1:200,000. At the end of surgery, study drug will be administered as per the standard FDA guidelines. Study drug will be administered by the investigator surgeon or members of surgical team under supervision of the investigator surgeon. Dose will be calculated by the surgeon based on the screening weight of each randomized participant as is done as the standard of care. Treatment compliance will be measured in terms of the subject receiving an injection of either Liposomal Bupivacaine 1.3% or Bupivacaine-Epinephrine 0.25%, 1:200,000 from the study personnel. No other forms of compliance will be measured. Reasons for any deviation will be recorded. Outcomes will be measured during post-operative hospital stay and until 1 year after surgery for extended follow up which is the standard protocol with cardiothoracic surgery.

Study coordinators will be responsible for data collection and will ensure that forms are completed and signed. Protected Health Information (PHI) will be recorded for tracking the participants through the course of the study. Subjects may be assigned an identification number for unbiased analysis, and will be linked to PHI separately. Data will be collected on data collection forms and subsequently entered into REDCap. Original signed consent forms, data collection forms and any relevant source documentation will be maintained for the duration of the study in locked file cabinets in the department of Cardiothoracic Surgery, Southern Illinois University, Springfield, IL. Electronic data will be stored on a secure server accessible via password-protected computer. Only authorized study personnel will have access to the study data. After completion of data analysis and final manuscript(s) approval, all non-electronic records will be sent to university records management for extended storage. Records will be stored for such a period after study completion as dictated by the university regulations. Adverse events, serious adverse events, discontinuation of drug administration due to adverse events will monitored for both the study drugs and will be reported to the Institutional Review Board.

Arms: arm 1: None arm 2: None
Interventions: intervention 1: Liposomal Bupivacaine intervention 2: Bupivacaine-Epinephrine
Intervention descriptions: intervention 1: Liposomal Bupivacaine 1.3% (Exparel), 20 ml vial for injection, administered subcutaneously at port site intervention 2: Bupivacaine-Epinephrine 0.25%, 1:200,000 (Marcaine with epinephrine), administered subcutaneously at port site

Protocol documents:
Prot_SAP_000.pdf: 
A Prospective, Randomized, Single-Blind, Active Control Trial to Compare Safety 
and Effectiveness Of Liposomal Bupivacaine (Exparel) to Standard bupivacaine 
HCl with epinephrine (Marcaine) for Pain Management in Patients Undergoing 
Video-Assisted Thoracoscopic Lobectomy (BEMP study) 
 
 
ClinicalTrials.gov NCT03682224 
 
 
Approval Date: 11/02/2020 


1
Version 1.5
October 27, 2020
$3URVSHFWLYH5DQGRPL]HG6LQJOH%OLQG$FWLYH&RQWURO7ULDOWR&RPSDUH6DIHW\
DQG (IIHFWLYHQHVV 2I /LSRVRPDO %XSLYDFDLQH ([SDUHO WR 6WDQGDUG EXSLYDFDLQH
+&O ZLWK HSLQHSKULQH 0DUFDLQH IRU 3DLQ 0DQDJHPHQW LQ 3DWLHQWV 8QGHUJRLQJ
9LGHR$VVLVWHG7KRUDFRVFRSLF/REHFWRP\%(03VWXG\
3ULQFLSDO,QYHVWLJDWRU
7UDYHV&UDEWUHH0'WFUDEWUHH#VLXPHGHGX
&R,QYHVWLJDWRUV
6WHSKHQ+D]HOULJJ0'
'DQXWD'\QGD0'
6WHSKHQ0DUNZHOO06
6RZP\DQDUD\DQDQ7KXSSDO0'3K'
&RRUGLQDWRU
4XDGLV(YDQV%6
.ULVWDO$GDPV%$&&53
Oct
,5%180%(5
,5%$33529$/'$7(


2
Version 1.5
October 27, 2020
7$%/(2)&217(176
 ,1752'8&7,21
%DFNJURXQGDQGUDWLRQDOH
 678'<2%-(&7,9(6
(IILFDF\DQGVDIHW\2XWFRPHV0HDVXUHG
 ,19(67,*$7,21$/3/$10(7+2'6
6WXG\'HVLJQ
&OLQLFDOVHWWLQJ
3DWLHQWSRSXODWLRQ
3.3.1. Inclusion Criteria
3.3.2. Exclusion Criteria:
6WXG\SURFHGXUHV
3.4.1. Summary
3.4.2. Informed consent
3.4.3. Treatments to Be Administered  
 3UHVFULELQJLQIRUPDWLRQ
 /DEHOLQJRI,QYHVWLJDWLRQDO
 6WRUDJHRI,QYHVWLJDWLRQDO
 $FFRXQWDELOLW\IRU,QYHVWLJDWLRQDO
3.4.4. Method of treatment assignment/Randomization
 6XEMHFW1XPEHULQJ
 5DQGRPL]DWLRQ
 $GPLQLVWUDWLRQDQGWLPLQJRI6WXG\GUXJ
 7UHDWPHQWFRPSOLDQFH
3.4.5. Assessment periods and associated observations and measurements
3.4.6. Concomitant Medications during the Study
L
3URKLELWHG&RQFRPLWDQW0HGLFDWLRQV3ULRUWR6WXG\7UHDWPHQW
LL
&RQFRPLWDQW0HGLFDWLRQVGXULQJWKH6WXG\
 678'<9$5,$%/(6
(IILFDF\
6DIHW\
&OLQLFDO
 67$7,67,&$/0(7+2'6$1''(7(50,1$7,212)6$03/(6,=(
 '$7$0$1$*(0(17$1'&21),'(17,$/,7<
 $66(660(172)6$)(7<
Oct
,5%180%(5
,5%$33529$/'$7(


3
Version 1.5
October 27, 2020
 ,1752'8&7,21
%DFNJURXQGDQGUDWLRQDOH
%DFNJURXQG
7KH86JRYHUQPHQWKDVPDGHWKHKLVWRULFGHFODUDWLRQRIWKHFXUUHQWRSLRLGFULVLVDVD
SXEOLF KHDOWK HPHUJHQF\ $QG WKRXJK WKLV DFWLRQ ZLOO DOORZ IRU H[SDQGHG DFFHVV WR
WHOHPHGLFLQH VHUYLFHV DQG UHDOORFDWH IXQGLQJ IRU DEXVH SURJUDPPLQJ LW UHPDLQV WKH
UHVSRQVLELOLW\ RI UHVHDUFKHUV WR SURSRVH FOLQLFDO VROXWLRQV WKDW FDQ LPSURYH SDWLHQW
RXWFRPHV)URPWRWKHGHDWKUDWHIURPV\QWKHWLFRSLRLGVVXFKDVIHQWDQ\O
LQFUHDVHGE\:KLOHDOORI,OOLQRLVZDVGLVWLQJXLVKHGDPRQJRWKHUVWDWHVZLWKD
VLJQLILFDQW LQFUHDVH LQ GUXJ RYHUGRVH GHDWK UDWHV IURP  E\ WKH &HQWHU IRU
'LVHDVH&RQWURO&'&DQG,OOLQRLV'HSDUWPHQWRI3XEOLF+HDOWK,'3+SHRSOHOLYLQJLQ
UXUDO FRPPXQLWLHV DUH PRUH OLNHO\ WR RYHUGRVH RQ SUHVFULSWLRQ SDLQ PHGLFDWLRQV WKDQ
SHRSOHLQFLWLHV7KLVSRVHVDQREVWDFOHIRUDOOFOLQLFLDQVDQGSDUWLFXODUO\WKRVHFKDUJHG
ZLWK SDLQ PDQDJHPHQW IROORZLQJ VXUJHU\ 7KRUDFLF VXUJHU\ UHTXLULQJ WKRUDFRWRP\ LV
ZLGHO\UHFRJQL]HGDVRQHRIWKHPRVWSDLQIXOVXUJLFDOSURFHGXUHVDQGLVDVVRFLDWHGZLWK
H[WHQGHGKRVSLWDOOHQJWKRIVWD\UHVSLUDWRU\PRUELGLW\DQGGHOD\HGSRVWVXUJLFDOUHWXUQ
RIIXQFWLRQ,QWHUFRVWDOQHUYHGDPDJHDQGPXVFXODUWUDXPDDUHFRQVLGHUHGWKHSULQFLSDO
FDXVHVRISRVWRSHUDWLYHSDLQDIWHUWKRUDFRWRP\0HGLFDOPDQDJHPHQWRISRVWRSHUDWLYH
SDLQ XWLOL]LQJ RSLRLGV DQG 16$,'V KDV EHFRPH WKH VWDQGDUG DSSURDFK IRU SRVW
WKRUDFRWRP\ DQDOJHVLD ZKHUHE\ GH PLQLPLV RSLRLG XVH LV D UHTXLUHPHQW IRU SDWLHQW
GLVFKDUJHFRQYHUVHO\FRQWULEXWLQJWRLQFUHDVHGKRVSLWDOOHQJWKRIVWD\
2YHUWKHODVWGHFDGHVFOLQLFLDQVKDYHOHYLHGLQFUHDVLQJHPSKDVLVRQPLQLPDOO\LQYDVLYH
VXUJLFDO WHFKQLTXHV UHGXFLQJ WKH ULVN RI LQWUDRSHUDWLYH FRPSOLFDWLRQV LQ VXUJHU\ E\
GHPRQVWUDEO\ UHOLDEOH LPSURYHPHQWV LQ SRVWRSHUDWLYH RXWFRPHV 9LGHRDVVLVWHG
WKRUDFRVFRSLF VXUJHU\ 9$76 LV D PLQLPDOO\ LQYDVLYH WHFKQLTXH ZKLFK HOLPLQDWHV WKH
QHFHVVLW\RIULEUHWUDFWLRQDQGVKULQNVWKHLQFLVLRQVL]HUHGXFLQJLQWHUFRVWDOQHUYHDQG
PXVFXODUWUDXPDWRSUHVHUYHGSXOPRQDU\IXQFWLRQ7KLVPHWKRGVUHOLHVRQYLVXDOL]DWLRQ
RIWKHPHGLDVWLQDODQDWRP\DQGVXUJLFDODSSDUDWXVXVLQJDFDPHUD)XUWKHUDGYDQFHPHQW
RYHUWKHODVWGHFDGHKDVEURDGHQHGWKHLQGLFDWLRQVIRU9$76XWLOL]DWLRQWRHQFRPSDVV
PRUHFRPSOH[SURFHGXUHVPDUJLQDOL]LQJWKHQHHGIRURSHQWKRUDFRWRP\SUDFWLFHV
7KRXJK9$76VKRZVFRPSDUDEOHEHQHILWVWRRSHQWKRUDFRWRP\EHLQJDVDIHUDOWHUQDWLYH
IRUHOGHUO\SDWLHQWVORZSRVWRSHUDWLYHSXOPRQDU\FRPSOLFDWLRQVGHFUHDVHGWUDXPDQRULE
VSUHDGLQJ ORZHU KRVSLWDOL]DWLRQ DQG D IDVWHU UHFRYHU\ SDWLHQWV VWLOO ULVN PRGHUDWHO\
VHYHUH DFXWH SRVWRSHUDWLYH SDLQ 6XFFHVVIXO PDQDJHPHQW RI SRVWRSHUDWLYH SDLQ DIWHU
9$76LVLQGLFDWLYHRIDGHTXDWHSRVWVXUJLFDOUHFRYHU\DVVXERSWLPDOSRVWRSHUDWLYHSDLQ
PDQDJHPHQWPD\OHDGWRFKURQLFSDLQZKLFKPD\EHRUEHFRPHQHXURSDWKLFLQQDWXUH
7KRUDFRWRP\LVVXVSHFWHGWRLQGXFHFKURQLFSDLQDWSHUFHQWRISDWLHQWVVXUYLYLQJD
\HDUDIWHUVXUJHU\ZKHUHSDLQZDVVHYHUHLQRIWKRVHFDVHVRISDWLHQWVZHUH
VKRZQE\RQHVWXG\WRKDYHSRVWRSHUDWLYHSDLQDWWKHWKRUDFRWRP\VLWHDIWHUPRQWKV
ZKLFK FDQ EH FUHGLWHG E\ D FRQVLGHUDEOH DPRXQW WR LQWHUFRVWDO QHUYH LQMXU\ ZLWK D
QHXURSDWKLFRULJLQ$QGWKRXJKVRPHSDWLHQWVLQWKLVVWXG\IRXQGSRVWWKRUDFRWRP\SDLQ
Oct
,5%180%(5
,5%$33529$/'$7(


4
Version 1.5
October 27, 2020
DIWHU\HDUVRPHRIWKRVHVDPHSDWLHQWVGLGQRWUHSRUWDQ\SDLQV\PSWRPVDWPRQWKV
/RQJWHUPIROORZXSVIRUSDLQPDQDJHPHQWDIWHUWKRUDFRWRP\DUHQRWVWDQGDUGFDUHSHU
FRPPRQSUDFWLFHV$GGLWLRQDOO\WKRXJKWKHUHLVDWUHDVXUHWURYHRIHYLGHQFHFRQQHFWLQJ
9$76WRFKURQLFSDLQYHU\OLWWOHKDVEHHQGRQHWRFRQFOXVLYHO\GHWDLOWKHUHODWLRQVKLS
EHWZHHQSRVWWKRUDFRVFRS\FKURQLFSDLQDQGRSLRLGGHSHQGHQFHZKLFKPD\DUULYHODWHU
LQ D SDWLHQWV¶ PHGLFDO KLVWRU\ 7KH JUDYLW\ RI WKH WUDQVSLULQJ $PHULFDQ SXEOLF KHDOWK
HPHUJHQF\KDVLQVSLUHGWKHUHVHDUFKFRPPXQLW\WRDUGHQWO\FRQVLGHUWKLVLVVXH0LQLPDOO\
LQYDVLYH SURFHGXUHV OLNH 9$76 DUH LQFRPSOHWH VROXWLRQV WR SRVWRSHUDWLYH SDLQ
PDQDJHPHQWZKHUHFKURQLFSDLQDQGGUXJGHSHQGHQFHUHTXLUHJUHDWHUFRQVLGHUDWLRQ
,QFUHDVLQJXWLOL]DWLRQRIQRQRSLRLGPHGLFDWLRQVDVVXUURJDWHRSLRLGPDQDJHPHQWIRUSRVW
WKRUDFRWRP\SDLQFRXOGSRWHQWLDOO\GLPLQLVKWKHPHGLFDOUHOLDQFHRQDQGLQFLSLHQWSDWLHQW
ULVNVLQFXUUHGDVDUHVXOWRIRSLRLGXVHIRU9$76SURFHGXUHV&RPSDULVRQVRIGLIIHUHQW
DQDOJHVLFPHWKRGVUHYHDOUHGXFHGLQFLGHQFHDQGLQWHQVLW\RIORQJWHUPSURFHGXUDOSDLQ
%XSLYDFDLQH+&OPDUNHWHGXQGHUWKHQDPHV0DUFDLQH6HQVRUFDLQHDQG9LYDFDLQHLV
WKHFXUUHQWQRQRSLRLGGUXJRIFKRLFHIRUWKRUDFLFHSLGXUDODQDOJHVLDLQSHUFHQWRI
VXUJLFDO FDVHV 0DUFDLQH EHKDYHV DV WKH DPLQRDPLGH DQHVWKHWLF 1-butyl-N-(2, 6-
dimethylphenyl) piperidine-2-carboxamide DFKLHYLQJ PRGHUDWH LQKLELWLRQ RI 1D  LRQ
WUDQVGXFWLRQDFURVVWKHQHXURQDOPHPEUDQHE\GHFUHDVLQJWKHPHPEUDQHSHUPHDELOLW\
DQG FRQVHTXHQWO\ LQKLELWLQJ WKH H[FLWDWLRQ RI QHXURQV WR GHSUHVV WKH SDLQ UHVSRQVH
$PLQRDPLGHDQHVWKHWLFVDUHFRPPRQO\DVVRFLDWHGZLWKK\SRWHQVLRQDQGFDQHQKDQFH
WKHK\SRWHQVLYHHIIHFWVRIDQXPEHURIDQWLK\SHUWHQVLYHGUXJV2WKHUDGYHUVHUHDFWLRQV
OLNHFDUGLDFDUUHVWEUDG\FDUGLDDSQHDDQGK\SRYHQWLODWLRQKDYHDOVREHHQDVVRFLDWHG
ZLWK$PLQRDPLGHORFDODQHVWKHWLFV0DUFDLQHLVDSSURYHGIRUORFDOL]HGDQDOJHVLDDQG
UHJLRQDOEORFNLQJE\WKH)RRGDQG'UXJ$GPLQLVWUDWLRQXQGHU+RVSLUD,QFDQGKDVVLQFH
UHFHLYHG ZLGH UHFRJQLWLRQ LQ WKRUDFLF VXUJHU\ IRU SRVWRSHUDWLYH SDLQ PDQDJHPHQW
IROORZLQJWKRUDFRWRP\&RQWUDULO\0DUFDLQHUHSRUWVRQO\DGXUDWLRQRIDFWLRQRIKRXUV
SHUGRVHDGPLQLVWUDWLRQ&RQWLQXRXVORFDODGPLQLVWUDWLRQRIEXSLYDFDLQHKDVEHHQVKRZQ
WRUHGXFHSDLQF\WRNLQHOHYHOVDQGRSLRLGUHTXLUHPHQWVSRVWRSHUDWLYHO\7KLVOLPLWDWLRQ
SUHVVXUHVDQHVWKHVLRORJLVWVXUJHRQVDQGQXUVLQJVWDIIWKURXJKLQRUGLQDWHVXUYHLOODQFH
RI D FRQVLVWHQW QHHG IRU DQDOJHVLD WR FRRUGLQDWH DGGLWLRQDO PHDVXUHV IRU SDLQ
PDQDJHPHQWVXFKDVWKHDGPLQLVWUDWLRQRI16$,'6DQGQDUFRWLFV$QFLOODU\VXSSRUWRI
EXSLYDFDLQH+&OLQIXVLRQXWLOL]LQJHSLQHSKULQHDQGRUSHULQHXUDOFDWKHWHUVFRPHVKRUWRI
UHPHGLDWLRQWRWKHOLPLWHGGXUDWLRQRIDFWLRQ7KHSRWHQWLDOWRLQFUHDVHWKHGXUDWLRQRI
DGHTXDWH ORFDO DQDOJHVLD E\ RWKHU QRYHO PHDQV PD\ KDYH DQ HIIHFW RQ GRVLQJ
UHTXLUHPHQWVDQGRIIHUDZD\WRUHGXFHWKHEORRGFRQFHQWUDWLRQRIEXSLYDFDLQH$
VWXG\ E\ WKH 8QLYHUVLW\ RI 7H[DV 0HGLFDO 6FKRRORI  SDUWLFLSDQWV XQGHUJRLQJ RSHQ
WKRUDFRWRP\ FRPSDULQJ WKH XVH RI WKH OLSRVRPDO EXSLYDFDLQH IRUPXODWLRQ NQRZQ DV
([SDUHODVDQLQWHUFRVWDOQHUYHEORFNWRWKHLUFXUUHQWWKRUDFLFHSLGXUDOVWDQGDUGUHVXOWHG
LQVLJQLILFDQWSDLQFRQWUROSRVWRSHUDWLYHO\
7KHOLSRVRPDOYHUVLRQRIEXSLYDFDLQHPDUNHWHGE\3DFLUD3KDUPDFHXWLFDOVLQLV
LQGLFDWHGIRUVLQJOHGRVHSRVWVXUJLFDODGPLQLVWUDWLRQLQWRVXUJLFDOVLWHWRSURGXFHORFDO
DQDOJHVLD9HVLFXODUHQFDSVXODWLRQKDVEHHQFRQILUPHGDVDQRYHOPHWKRGRIH[WHQGLQJ
Oct
,5%180%(5
,5%$33529$/'$7(


5
Version 1.5
October 27, 2020
GHOLYHU\ RI DQHVWKHVLD DQG DV D PXOWLYHVLFOH OLSRVRPH IRUPXODWLRQ RI EXSLYDFDLQH
([SDUHOSURYLGHVDQH[WHQGHGGXUDWLRQRIDFWLRQUHSRUWLQJ!KRXUVRISRVWLQMHFWLRQ
DQDOJHVLD /LSRVRPHV DUH ORDGHG ZLWK EXSLYDFDLQH E\ DQ DPPRQLXP VXOIDWH JUDGLHQW
HVWDEOLVKHGDWDQDSSURSULDWHS+IRUFRPSOHWHVDWXUDWLRQRIWKHYHVLFOHVZLWKEXSLYDFDLQH
7KH GUXJ LV UHOHDVHG JUDGXDOO\ DIWHU GLVSHQVDWLRQ WR SURYLGH VWHDG\ DQDOJHVLD WR WKH
DIIHFWHG DUHD ([SDUHO ZDV LQLWLDOO\ DSSURYHG E\ WKH )'$ IRU WUHDWPHQW RI SDWLHQWV
XQGHUJRLQJEXQLRQHFWRPLHVRUKHPRUUKRLGHFWRPLHV7KH)'$KDVVLQFHEURDGHQHGWKH
LQGLFDWLRQ RI ([SDUHO WR ³DGPLQLVWUDWLRQ LQWR VXUJLFDO VLWH WR SURGXFH SRVWVXUJLFDO
DQDOJHVLD´
:KLOHDVVHVVLQJZKHWKHUXVHRIDKLJKHUILGHOLW\DQDOJHVLDZLOODIIHFWWKHUHTXLUHPHQWIRU
QDUFRWLF DGPLQLVWUDWLRQ IRU SRVWRSHUDWLYH SDLQ DQG WKH ULVN RI RSLRLG GHSHQGHQFH DQG
DEXVH REVHUYHG ZKHQ SRVWRSHUDWLYH SDLQ LV WUHDWHG ZLWK D ORQJHU VWHDG\ UHOHDVH RI
DQHVWKHVLDRYHUWLPHWKLVVWXG\DLPVWRFRQVLGHURXWFRPHVUHODWHGWRSDWLHQWKRVSLWDO
FRVWVDVZHOODVVKRUWDQGORQJWHUPSDLQDVVHVVPHQWDIWHUKRVSLWDOGLVFKDUJH
+RVSLWDOFRVWVDVVRFLDWHGZLWK9$76DQHVWKHVLDQDUFRWLFXVHLQUXUDO,OOLQRLVFRPPXQLW\
KDVQRWEHHQVXEMHFWHGWRWKHGXHVFUXWLQ\QHFHVVDU\WRXQGHUVWDQGWKHHIIHFWRIWKH
RSLRLGFULVLVWKH&RXQFLORI(FRQRPLF$GYLVRUVUHSRUWRQWKLVLQVXUJHQFHHVWLPDWHVWKH
RYHUDOOQDWLRQDOFRVWLQDWQHDUO\ELOOLRQDQGFOLPELQJ,'3+VHPLDQQXDOUHSRUW
RQRSLRLGWUHQGVLQKRVSLWDOL]DWLRQVDQGHPHUJHQF\GHSDUWPHQWYLVLWVVKRZFRQWLQXHG
LQFUHDVHDQQXDOO\VLQFHWKHDQGDQRYHUDOOXSZDUGWUHQGVLQFH$UHSRUWE\
6,86FKRRORI0HGLFLQHSODFHVHVWLPDWHGGLUHFWPHGLFDOFRVWVLQDWELOOLRQ$G
FDYHDW WKHVH HVWLPDWHV LQFOXGHV ORQJ WHUP GDWD FROOHFWHG RQ GRZQVWUHDP HIIHFWV RI
RSLRLGDEXVHZKLFKKDVEHHQXQIRUWXQDWHO\DQGLQGHOLEO\FRUUHODWHGWRSUHVFULSWLRQVIRU
DQHVWKHVLDGXULQJVXUJHU\LQFOXGLQJWKHULVHLQKHDOWKFDUHUHVRXUFHVXWLOL]HGRYHUWLPHE\
RSLRLGDEXVHUVDVFRPSDUHGWRWKHLUQRQDGGLFWHGSHHUVFRVWVWRWKHFULPLQDOMXVWLFH
V\VWHPDQGIDWDOLW\FRVWVRIORVWSRWHQWLDOHDUQLQJV7KLVVWXG\GRHVQRWLQWHQGWRDVVHVV
WKHLPSDFWRQRWKHUGRZQVWUHDPHFRQRPLFIDFWRUVWKRXJKE\FROOHFWLQJFRPSDULVRQGDWD
RQ KHDOWKFDUH FKDUJHV DV D UHVXOW RI QDUFRWLF UHTXLUHPHQWV IURP XVH RI ORFDO
DGPLQLVWUDWLRQRI([SDUHODQG0DUFDLQHIRU9$76WKHSUHIHUUHGVXUJLFDOWHFKQLTXHIRU
OXQJ GLVHDVHV E\ 6,8 0HGLFLQH &DUGLRWKRUDFLF VXUJHRQV ZH FDQ LQFUHDVH RXU
XQGHUVWDQGLQJRIWKHGLVSDULW\WKDWRSLRLGFULVLVSODJXHVRQWKHERWWRPOLQHRIRXUKRVSLWDO
DQGWKHSRFNHWVRILWVSDWURQV7KRXJKERWKRIWKHVHGUXJVSURYLGHDQRQRSLRLGDQDOJHVLF
DQG DUH DYDLODEOH DQG LQGLFDWHG IRU WKH LQWHQGHG XVH WKH JURVV GLIIHUHQFHV LQ WKHLU
GXUDWLRQV RI DFWLYLW\ XQGHUVFRUH D SRWHQWLDOO\ VLJQLILFDQW GLIIHUHQFH LQ WKH QHFHVVLW\ RI
QDUFRWLFXVHIRUSRVWWKRUDFRWRP\SDLQZKLFKZHSODQWRIXUWKHUGHVFULEHLQWKHSURSRVHG
UHVHDUFK7REHDEOHWRHIILFDFLRXVO\GLVWLQJXLVKEHWZHHQWKHWZRGUXJVLVLQWKHEHVW
LQWHUHVWRIRXUSDWLHQWV
&XUUHQWO\ WKHUH LV YHU\ OLWWOH SXEOLVKHG GDWD UHSUHVHQWLQJ WKHVH RXWFRPHV LQ FRQVRUW
*URZLQJSUHIHUHQFHIRUORFDODQDOJHVLDDQGLQWHUFRVWDOQHUYHEORFNLQJZLWK([SDUHOIRU
SDLQDIWHUWKRUDFRWRP\SUHVHQWVDXQLTXHRSSRUWXQLW\WRVWXG\WKHHIIHFWVRQFRVWOHQJWK
RI KRVSLWDO VWD\ DQG SULPDULO\ WKH FRPSDUDWLYH GRZQVWUHDP HIIHFW RQ QDUFRWLF
Oct
,5%180%(5
,5%$33529$/'$7(


6
Version 1.5
October 27, 2020
UHTXLUHPHQWVSDLQPDQDJHPHQW3HURXURZQTXHU\FOLQLFDOWULDOFXUUHQWO\UHJLVWHUHG
ZLWKFOLQLFDOWULDOVJRYFRPSDUHV([SDUHODQG0DUFDLQHSURVSHFWLYHO\IRUSRVWRSHUDWLYH
SDLQPDQDJHPHQWIROORZLQJOXQJVXUJHU\1RRWKHUVWXG\FXUUHQWO\LQWHQGVWRDQDO\]H
FKURQLFQHXURSDWKLFSDLQRSLRLGXVDJHDQGKRVSLWDOFRVWGDWD,QRXUFXUUHQWFOLQLFDO
VHWWLQJWKHXVHRI0DUFDLQHYHUVXV([SDUHOLVEDVHGSXUHO\RQSK\VLFLDQSUHIHUHQFH
 678'<2%-(&7,9(6
7KHK\SRWKHVLVLVWKHSRVVLELOLW\RIOLSRVRPDOEXSLYDFDLQHSURYLGLQJPRUHUHOLHIZLWKOHVV
QHHG RI QDUFRWLFV ZKHQ FRPSDUHG WR VWDQGDUG EXSLYDFDLQH 7R FRPSDUH SDLQ
PDQDJHPHQW IROORZLQJ ORFDO LQILOWUDWLRQ RI OLSRVRPDO EXSLYDFDLQH ([SDUHO YHUVXV
VWDQGDUG EXSLYDFDLQH +&O ZLWK HSLQHSKULQH 0DUFDLQH DIWHU 9$76 YLGHRDVVLVWHG
WKRUDFRVFRSLFVXUJHU\OREHFWRP\7KLVZLOOEHDFFRPSOLVKHGE\HYDOXDWLQJWRWDORSLRLG
XVDJHDQGSDWLHQWUHSRUWHGSDLQVFRUHV
(IILFDF\2XWFRPHV0HDVXUHG
2.1.1.
Primary Outcomes 
L7RWDOPRUSKLQHHTXLYDOHQWVFRQVXPHGGXULQJKRXUVSRVWRS
2.1.2.
Secondary Outcomes 
L
3DWLHQWVHOIUHSRUWHGSDLQYLVXDODQDORJVFDOHVFRUH
LL
1DUFRWLFRUSDLQPHGLFDWLRQVFRQVXPHGWKURXJKRXWKRVSLWDOL]DWLRQDQGGXULQJ
ILUVWGD\VPRQWKVDQG\HDUSRVWOREHFWRP\
LLL
,QFLGHQFHRI3DUHVWKHVLD
LY
7LPHXQWLOILUVWRSLRLGXVDJH
Y
$QWLHPHWLFXVDJH
YL
/HQJWKRIKRVSLWDOVWD\
YLL
3RVWRSHUDWLYH FRPSOLFDWLRQV HJ SQHXPRQLD SXOPRQDU\ FRPSOLFDWLRQV
ZRXQGLQIHFWLRQVHWF
YLLL
7LPHWRDPEXODWLRQ
L[
7LPHWRILUVWERZHOPRYHPHQW
[
7LPHWRFKHVWWXEHUHPRYDO
[L
3HDNH[SLUDWRU\IORZPHDVXUHPHQWV
[LL
,QWUDRSHUDWLYHYHUVXVSRVWRSHUDWLYHSDLQPDQDJHPHQWFRVWV
[LLL
2YHUDOO+RVSLWDO&RVW
Oct
,5%180%(5
,5%$33529$/'$7(


7
Version 1.5
October 27, 2020
6DIHW\2XWFRPHV0HDVXUHG
L
$GYHUVHHYHQWVVHULRXVDGYHUVHHYHQWV6$(V
LL
6XVSHFWHGDGYHUVHGUXJUHDFWLRQV
 ,19(67,*$7,21$/3/$1
6WXG\'HVLJQ
7KLV LV D SURVSHFWLYH UDQGRPL]HG VLQJOHEOLQG DFWLYH FRQWURO WULDO IRU SDWLHQWV
XQGHUJRLQJHOHFWLYHOREHFWRP\6XEMHFWVZLOOEHUDQGRPO\DVVLJQHGWRUHFHLYHHLWKHU
OLSRVRPDO EXSLYDFDLQH ([SDUHO WHVW JURXS $ RU VWDQGDUG EXSLYDFDLQH +&O ZLWK
HSLQHSKULQH0DUFDLQHDFWLYHFRPSDUDWRUJURXS%GXULQJVXUJHU\3DLQPDQDJHPHQW
ZLOOEHPRQLWRUHGYLDRSLRLGXVDJHDQGYLVXDOSDLQDVVHVVPHQWWKURXJKRXWWKHKRVSLWDO
VWD\DQGDWSRVWRSHUDWLYHGD\PRQWKDQG\HDUIROORZXSYLVLWV2YHUDOOVWXG\
VFKHPDLVGHVFULEHGLQ)LJXUHDWWKHHQGRIWKLVGRFXPHQW
&OLQLFDO6HWWLQJ
6WXG\ZLOOEHFRQGXFWHGDW6,80HGLFLQH&OLQLFVDQG0HPRULDO0HGLFDO&HQWHU
3DWLHQWSRSXODWLRQ
6WXG\SRSXODWLRQLQFOXGHVSDWLHQWVXQGHUJRLQJHOHFWLYHVWDQGDUGRIFDUHOREHFWRP\
%DVHGRQRXUSRZHUDQDO\VLVVXEMHFWVLQHDFKUDQGRPL]HGJURXSQHHGWREH
LQFOXGHGVHHSection 5, Statistical Analyses7DNLQJLQWRFRQVLGHUDWLRQDSRWHQWLDO
ORVVRISDWLHQWVGXHWRZLWKGUDZDOORVWWRIROORZXSRURWKHUUHDVRQVSDWLHQWV
ZLOOLQLWLDOO\EHHQUROOHGDQGUDQGRPL]HGWRDWWDLQHYDOXDEOHVXEMHFWVDWWKHHQGRI
VWXG\\HDUIROORZXS:HHVWLPDWHWKLVVWXG\ZLOOWDNHXSWRWKUHH\HDUVWRFRPSOHWH
RXUHQUROOPHQW
3.3.1. Inclusion Criteria

$GXOWDWOHDVW\HDUVRIDJH

6XEMHFWQHHGVHOHFWLYHOREHFWRP\IRU16&/&

:LOOLQJWRFRPSO\ZLWKDOODVSHFWVRISURWRFROLQFOXGLQJSURYLGLQJLQIRUPDWLRQ
DERXWRSLRLGXVDJHIRUSRVWVXUJLFDOSDLQDQGVLJQHGLQIRUPHGFRQVHQW
3.3.1. Exclusion Criteria:

\HDUVRIDJH!\HDUVRIDJH

,QDELOLW\RUXQZLOOLQJQHVVWRFRQVHQW

(PHUJHQF\VXUJHU\
Oct
,5%180%(5
,5%$33529$/'$7(


8
Version 1.5
October 27, 2020

3UHYLRXVLSVLODWHUDOWKRUDFLFVXUJHU\

1HHGIRURSHUDWLYHSOHXUHFWRP\RUSOHXURGHVLVDVWKHSULPDU\RSHUDWLRQ

&KURQLF1DUFRWLFXVHIRURUPRUHPRQWKV

$Q\H[WHQVLYHQDUFRWLFXVHLQWKHPRQWKSHULRGSULRUWRVFUHHQLQJZLWKDQ
H[FHSWLRQIRUWKHXVHRIQDUFRWLFVFRPPHQVXUDWHZLWKVWDQGDUGFDUHGLDJQRVWLF
SURFHGXUHVIRU9$76/REHFWRP\

$OOHUJLHV WR EXSLYDFDLQH RU RWKHU ORFDO DQHVWKHWLFV QDUFRWLFV 16$,'V RU
DFHWDPLQRSKHQ

0RGHUDWH WR VHYHUH KHSDWLF LPSDLUPHQW $/7 RU $67 YDOXH JUHDWHU WKDQ 
WLPHVWKHXSSHUOLPLWRIQRUPDO
 6HYHUHUHQDOLPSDLUPHQWRUHQGVWDJHUHQDOIDLOXUHGLVHDVHFUHDWLQLQHJUHDWHU
WKDQPJGO
 +LVWRU\RISHSWLFXOFHUDWLYHGLVHDVH
 6HYHUH FKURQLF REVWUXFWLYH SXOPRQDU\ GLVHDVH &23' GXH WR /956 OXQJ
YROXPHUHGXFWLRQVXUJHU\
 3UHJQDQF\
 1HHGIRUFRQYHUVLRQIURPD9LGHR$VVLVWHG7KRUDFLF6XUJHU\SURFHGXUHWRDQ
RSHQWKRUDFRWRP\
 6XEMHFWVZKRDUHLQFDUFHUDWHG
 6XEMHFW KDV EHHQ WUHDWHG ZLWK DQ H[SHULPHQWDO GHYLFH ZLWKLQ  GD\V RU
UHFHLYHGDQH[SHULPHQWDODJHQWZLWKLQWKHORQJHURIGD\VRUILYHKDOIOLYHV
2UVXEMHFWLVFXUUHQWHQUROOHGLQDQRWKHUFOLQLFDOWULDO
 8QDEOHWRIROORZSURWRFROGLUHFWLRQVGXHWRRUJDQLFEUDLQRUSV\FKLDWULFGLVHDVH
 +LVWRU\RIDOFRKROLVPRUDQ\RWKHUVXEVWDQFHDEXVHZKLFKLQWKHRSLQLRQRIWKH
LQYHVWLJDWRUZRXOGDIIHFWFRPSOLDQFHZLWKWKHSURWRFRO
6WXG\SURFHGXUHV
3.4.1. Summary
$OOSDWLHQWVVFKHGXOHGIRUVXUJLFDOFRQVXOWZLWK&DUGLRWKRUDFLF6XUJHU\IRUSRVVLEOH
9$76OREHFWRP\ZLOOEHSUHVFUHHQHGIRULQLWLDOHOLJLELOLW\FULWHULD6XEMHFWVZKRHOHFWWR
JRIRUZDUGZLWKVXUJHU\ZLOOEHSUHVHQWHGZLWKWKHRSSRUWXQLW\WRSDUWLFLSDWHLQWKH
VWXG\,QIRUPHGFRQVHQWIRUPZLOOEHGLVFXVVHGLQGHWDLODWWKHFOLQLFRU00&IRULQ
SDWLHQWSRWHQWLDOVXEMHFWVE\DXWKRUL]HGVWXG\SHUVRQQHO3DWLHQWZLOOEHJLYHQWLPHWR
UHYLHZ WKH LQIRUPHG FRQVHQW ZLWK IDPLO\ LI VR GHVLUHG $IWHU WKH SDWLHQW YROXQWDULO\
DJUHHVWRSDUWLFLSDWHVLJQ,&)WKHLULQFOXVLRQH[FOXVLRQFULWHULDZLOOEHUHYLHZHGDJDLQ
Oct
,5%180%(5
,5%$33529$/'$7(


9
Version 1.5
October 27, 2020
EDVHG RQ 62& WHVWLQJ WR HQVXUH FRQWLQXHG HOLJLELOLW\ 3DWLHQW GDWD VXFK DV YLWDOV
SK\VLFDO H[DPLQDWLRQ 3( PHGLFDWLRQV DQG PHGLFDO DQG VXUJLFDO KLVWRU\ ZLOO EH
UHFRUGHGRUREWDLQHGIURPWKH(+56XEMHFWVZLOOEHUDQGRPL]HGWRRQHRIWZRJURXSV
WHVW$DQGDFWLYHFRQWURO%1LJKWRUPRUQLQJRIVFKHGXOHGVXUJHU\$WWKHHQGRI
VXUJHU\VWXG\GUXJZLOOEHDGPLQLVWHUHGDVGHVFULEHGLQGHWDLOVEHORZSHUWKHVWDQGDUG
)'$JXLGHOLQHV2XWFRPHVZLOOEHPHDVXUHGGXULQJSRVWRSHUDWLYHKRVSLWDOVWD\DQG
XQWLO\HDUDIWHUVXUJHU\IRUH[WHQGHGIROORZXSZKLFKLVWKHVWDQGDUGSURWRFROZLWK&7
VXUJHU\$VFKHGXOHIRUDOODVVHVVPHQWVWKURXJKRXWWKHVWXG\LVGHVFULEHGLQWDEOH
DWWKHHQGRIWKLVGRFXPHQW
3.4.2. Informed consent
$OOSDUWLFLSDQWVZLOOEHUHTXLUHGWRSURYLGHZULWWHQLQIRUPHGFRQVHQW7KHVWXG\VWDII
ZLOOLQWURGXFHWKHVWXG\WRSRWHQWLDOO\HOLJLEOHSDWLHQWV7KHSULQFLSDORUFRLQYHVWLJDWRUV
DQGRUVWXG\FRRUGLQDWRUVZLOOUHYLHZWKHLQIRUPHGFRQVHQWGRFXPHQWZLWKWKHVXEMHFW
7KHVXEMHFWZLOOEHSURYLGHGLQIRUPDWLRQUHODWHGWRWKHVWXG\SXUSRVHSURFHGXUHV
SRWHQWLDO ULVNV DQG EHQHILWV WR SDUWLFLSDWLRQ YROXQWDU\ QDWXUH RI WKHLU SRWHQWLDO
SDUWLFLSDWLRQDQGSURYLGHWKHPDQRSSRUWXQLW\WRDVNDQGKDYHDOOTXHVWLRQVDQVZHUHG
SULRUWRREWDLQLQJDQ\VLJQDWXUH$VWXG\LQYHVWLJDWRUZLOOEHDYDLODEOHWRDQVZHUDQ\
TXHVWLRQV 6XEMHFWV ZLOO QRW EH FRPSHQVDWHG IRU SDUWLFLSDWLRQ DQG WKHUH DUH QR
DGGLWLRQDO UHVHDUFKUHODWHG FRVWV WR VXEMHFWV IRU SDUWLFLSDWLRQ LQ WKH VWXG\  %RWK
PHGLFDWLRQVDQGWKHVXUJHU\DUHVWDQGDUGRIFDUHDQGZLOOEHELOOHGDFFRUGLQJO\
3.4.3. Treatments to Be Administered
 3UHVFULELQJLQIRUPDWLRQ
•
%XSLYDFLQHHSLQHSKULQH0DUFDLQH6HH'UXJ,QVHUW
VXEPLWWHG
L FRQFHQWUDWLRQXSWRPJZLWKHSLQHSKULQHDGPLQLVWHUHG
DVDQVXEFXWDQHRXVLQMHFWLRQDWWKHSRUWVLWH
•
)LQDOGRVLQJZLOOEHGHWHUPLQHGE\WKHSK\VLFLDQEDVHGRQ
SDWLHQW ZHLJKW DQG LV LQGLYLGXDOL]HG RQ D FDVH E\ FDVH
EDVLV
•
0D[LPXPGRVDJHPJKRXUV
•
%XSLYDFLQHOLSRVRPDO([SDUHO6HH'UXJ,QVHUWVXEPLWWHG
L 8SWRPJP/DGPLQLVWHUHGDVDVXEFXWDQHRXVLQMHFWLRQ
DWWKHSRUWVLWHGLOXWHGWRDILQDOFRQFHQWUDWLRQRIPJP/ZLWK
P/QRUPDOVDOLQH
Oct
,5%180%(5
,5%$33529$/'$7(


10
Version 1.5
October 27, 2020
•
)LQDOGRVLQJZLOOEHGHWHUPLQHGE\WKHSK\VLFLDQEDVHGRQ
SDWLHQW ZHLJKW DQG LV LQGLYLGXDOL]HG RQ D FDVH E\ FDVH
EDVLV
•
0D[LPXPGRVDJHPJPO
 /DEHOLQJRI,QYHVWLJDWLRQDO3URGXFWV
3KDUPDF\ ZLOO GLVSHQVH WKH LQYHVWLJDWLRQDO GUXJ SHU UDQGRPL]DWLRQ DVVLJQPHQW
DQGODEHOOHGSHUKRVSLWDOVWDQGDUGV7KHVHDUH)'$DSSURYHGSURGXFWVWKDWDUH
ERWKXVHGDVVWDQGDUGRIFDUH
 6WRUDJHRI,QYHVWLJDWLRQDO3URGXFWV
,QYHVWLJDWLRQDOSURGXFWVZLOOEHVWRUHGLQWKH0HPRULDO0HGLFDO&HQWHU3KDUPDF\
SHUKRVSLWDOJXLGHOLQHV$FFRXQWDELOLW\IRU,QYHVWLJDWLRQDO3URGXFWV
$FFRXQWDELOLW\ RI WKH LQYHVWLJDWLRQDO SURGXFWV ZLOO EH DFKLHYHG SHU 0HPRULDO
0HGLFDO&HQWHUJXLGHOLQHVE\00&VWDIIDVGRQHSHUVWDQGDUGSURWRFRO
3.4.4. Method of treatment assignment/Randomization
 6XEMHFW1XPEHULQJ
6XEMHFWVZLOOEHDVVLJQHGDXQLTXHFRQVHFXWLYHVXEMHFWQXPEHUGLJLWV3UHFHGLQJWKH
GLJLWVZLOOEHWKHOHWWHUV(0([SDUHO0DUFDLQHWRLGHQWLI\WKHVWXG\)RUH[DPSOHVXEMHFW
QXPEHUV ZLOO EH (0 (0 HWF LQ FRQVHFXWLYH RUGHU 6XEMHFW QXPEHUV RQFH
DVVLJQHGZLOOQRWEHUHXVHG
 5DQGRPL]DWLRQ
$UDQGRPL]DWLRQVFKHPDZLOOEHSHUIRUPHGE\DVHFRQGDU\VWDWLVWLFLDQDWWKH&HQWHUVIRU
&OLQLFDO5HVHDUFKIRUDOOSDWLHQWVDQGZLOOEHOLVWHGRQRQHOLVWWKDWZLOOEHSURYLGHGWR
00&SKDUPDF\DQGZLOODOVREHVWRUHGE\WKH5HVHDUFK&RRUGLQDWRUVIRUUHIHUHQFH7KH
SDWLHQW ,' DQG UDQGRPL]DWLRQ DVVLJQPHQW ZLOO EH VHQW WR WKH SKDUPDF\ DORQJ ZLWK
VFUHHQLQJ ZHLJKW RI WKH VXEMHFW 7KH VXEMHFWV DQG VWXG\ VWDWLVWLFLDQV ZLOO UHPDLQ
EOLQGHGWRWKHWUHDWPHQWDVVLJQPHQWVWKURXJKRXWWKHFRXUVHRIWKHVWXG\ZKLOHWKHVXUJLFDO
WHDP DQG FRRUGLQDWRUV ZLOO QRW EH EOLQGHG 'DWD ZLOO EH DQDO\]HG E\ WKH EOLQGHG
VWDWLVWLFLDQVWRHQVXUHPLQLPDOELDV
 $GPLQLVWUDWLRQDQGWLPLQJRI6WXG\GUXJ
Oct
,5%180%(5
,5%$33529$/'$7(


11
Version 1.5
October 27, 2020
6WXG\GUXJZLOOEHDGPLQLVWHUHGE\WKHLQYHVWLJDWRUVXUJHRQRUPHPEHUVRIVXUJLFDOWHDP
XQGHUVXSHUYLVLRQRIWKHLQYHVWLJDWRUVXUJHRQDVGHVFULEHGEHORZ
7HVW JURXS $ $W WKH HQG RI WKH VXUJLFDO SURFHGXUH SDWLHQWV LQ JURXS $ ZLOO UHFHLYH
LQMHFWLRQVRIOLSRVRPDOEXSLYDFDLQH([SDUHOVWDQGDUGGRVHEDVHGRQSDWLHQW¶VVFUHHQLQJ
ZHLJKWGHOLYHUHGYLDDJDXJHQHHGOHLQWRWKHVXUURXQGLQJFXWDQHRXVDQGGHHSWLVVXH
LQFOXGLQJWKHSHULRVWHXPDURXQGWKHWKRUDFRVFRSLFSRUWLQFLVLRQVLWHVDIWHUFORVXUH
$FWLYH&RPSDUDWRU*URXS%$WWKHHQGRIWKHVXUJLFDOSURFHGXUHSDWLHQWVLQJURXS%
ZLOOUHFHLYHLQMHFWLRQVRIVWDQGDUGEXSLYDFDLQH+&OZLWKHSLQHSKULQHGHOLYHUHGYLD
 JDXJH QHHGOH LQWR WKH VXUURXQGLQJ FXWDQHRXV DQG GHHS WLVVXH LQFOXGLQJ WKH
SHULRVWHXPDURXQGWKHWKRUDFRVFRSLFSRUWLQFLVLRQVLWHVDIWHUFORVXUH
•
Rationale for Selection of Doses
'RVH ZLOO EH FDOFXODWHG E\ WKH SK\VLFLDQ EDVHG RQ WKH VFUHHQLQJ ZHLJKW RI HDFK
UDQGRPL]HG SDWLHQW DV LV GRQH LQ WKH VWDQGDUG ZD\ 7KLV ZLOO SURYLGH UHDVRQDEOH
FRPSDULVRQRIVWDQGDUGGRVHRIHDFKGUXJWKDWZRXOGKDYHEHHQJLYHQIRUDQ\LQGLYLGXDO
SDWLHQW
 7UHDWPHQWFRPSOLDQFH
7UHDWPHQWFRPSOLDQFHZLOOEHPHDVXUHGLQWHUPVRIWKHVXEMHFWUHFHLYLQJDQLQMHFWLRQRI
HLWKHU([SDUHORU0DUFDLQHZLWKHSLQHSKULQHIURPWKHVWXG\SHUVRQQHO1RRWKHUIRUPV
RIFRPSOLDQFHZLOOEHPHDVXUHG
5HDVRQVIRUDQ\GHYLDWLRQIURPWKHDGPLQLVWUDWLRQRIOHVVWKDQRIWKHLQYHVWLJDWLRQDO
SURGXFWVGRVHPXVWEHUHFRUGHGLQWKHVXEMHFW¶VPHGLFDOUHFRUGV
3.4.5. Assessment periods and associated observations and measurements
'HVFULEHGLQVFKHGXOHRIDVVHVVPHQWVLQ7DEOH
3.4.6. Concomitant Medications during the Study
 3URKLELWHG&RQFRPLWDQW0HGLFDWLRQV3ULRUWR6WXG\7UHDWPHQW
$Q\ FKURQLFKDELWXDO XVH RI QDUFRWLFV RU ZLWKLQ RQH SHULRG EHIRUH FRQVHQW DQG
VFUHHQLQJZLOOEHH[FOXVLRQDU\$Q\XVHRIQDUFRWLFVEHWZHHQVFUHHQLQJDQGRSHUDWLYH
GD\ ZLOO EH FODVVLILHG DV VFUHHQ IDLOXUH LI QRW UDQGRPL]HG RU ZLWKGUDZQ LI
UDQGRPL]DWLRQKDVEHHQGRQH
Oct
,5%180%(5
,5%$33529$/'$7(


12
Version 1.5
October 27, 2020
 &RQFRPLWDQW0HGLFDWLRQVGXULQJWKH6WXG\
'HWDLOV RI DOO KRPH PHGLFDWLRQV SDLQ PDQDJHPHQW PHGLFDWLRQV DQG DQWLQDXVHD
PHGLFDWLRQVZLOOEHUHFRUGHG
 678'<9$5,$%/(6
(IILFDF\
3HUFHQWDJHRIVXEMHFWVZLWKRQHRUPRUHFRPSRQHQWVRIDPDMRUPRUELGLW\XSWR'D\
SRVWRSHUDWLRQ&RPSRQHQWVRIPRUELGLW\
D
0('XVDJH0RUSKLQH(TXLYDOHQW'RVHWKHDPRXQWRIPRUSKLQHDQRSLRLG
GRVHLVHTXDOWRXVLQJKWWSFOLQFDOFFRP2SLRLGV
E
9$6IRU3DLQ9LVXDO$QDORJ6FDOH
6DIHW\
7KHIROORZLQJVDIHW\YDULDEOHVZLOOEHDVVHVVHGLQWKLVVWXG\SHUWKH'603'DWD
6DIHW\0RQLWRULQJ3ODLQ
D
$GYHUVHHYHQWVVHULRXVDGYHUVHHYHQWV6$(VDQGGLVFRQWLQXDWLRQVGXH
WR$(V
E
3K\VLFDOH[DPLQDWLRQ
F
9LWDOVLJQV
&OLQLFDO
D
3RVWRSHUDWLYH PRUWDOLW\ GHILQHG DV WKH GHDWKV RFFXUULQJ GXULQJ SULPDU\
KRVSLWDOVWD\RUSULRUWRWKSRVWRSHUDWLYHGD\
E
$GGLWLRQDOVXUJLFDOLQWHUYHQWLRQGHILQHGDVKDYLQJWRUHHQWHUWKHRSHUDWLQJ
URRPEHFDXVHRIEOHHGLQJSQHXPRWKRUD[SURORQJHGDLUOHDNRUDQ\RWKHU
FRPSOLFDWLRQDVVRFLDWHGZLWKSULPDU\VXUJHU\
F
3URORQJHGPHFKDQLFDOYHQWLODWLRQGHILQHGDVPHFKDQLFDOYHQWLODWLRQWKDW
H[FHHGVKRXUVIURPFORVXUHXQWLOH[WXEDWLRQ
G
3URORQJHGDLUOHDNGHILQHGE\WKH6767KRUDFLF6XUJHU\'DWDEDVHDVDQDLU
OHDNWKDWSHUVLVWVIRUJUHDWHUWKDQSRVWRSHUDWLYHGD\V
Oct
,5%180%(5
,5%$33529$/'$7(


13
Version 1.5
October 27, 2020
H
&RPSOLFDWLRQV LQFOXGLQJ FDUGLDF VXFK DV FDUGLDF WDPSRQDGH DWULDO
ILEULOODWLRQRUFDUGLDFKHUQLDWLRQ
I
,QIHFWLRQ GHILQHG DV SUHVHQFH RI VXUJLFDO LQFLVLRQ LQIHFWLRQ DEVFHVVHV
SQHXPRQLDRUEORRGVWUHDPLQIHFWLRQVRUVHSVLV7KLVFRXOGEHSDWLHQWVZKR
DUHWUHDWHGZLWKDQWLELRWLFVRUVKRZDSRVLWLYHFXOWXUH
J
6WURNH GHILQHG DV QHXURORJLFDO GHILFLWV RI DEUXSW RQVHW PDGH E\ FOLQLFDO
GLDJQRVLVWKDWZHUHFDXVHGE\DGLVUXSWLRQRIFHUHEUDOEORRGIORZ
K
3URORQJHGKRVSLWDOVWD\GHILQHGDVGD\VSRVWRSHUDWLYHO\
L
3URORQJHG ,&8 VWD\ GHILQHG DV ,&8 VWD\ ORQJHU WKDQ  KRXUV SRVW
RSHUDWLYHO\RUUHHQWHULQJWKH,&8EHIRUHGD\SRVWRSHUDWLYHIROORZXS
 67$7,67,&$/0(7+2'6$1''(7(50,1$7,212)6$03/(6,=(
%DVHGRQWKHUHVXOWVRIWKH3DUDVFRQGRODHWDOVWXG\DSRZHUDQDO\VLVZDVSHUIRUPHGWR
GHWHUPLQHWKHQHFHVVDU\VDPSOHVL]HLQWKHWUHDWPHQWDUPVIRUWKHSURSRVHGVWXG\
:KLOHWKH3DUDVFRQGRODVWXG\RQO\H[DPLQHGLQSDWLHQWQDUFRWLFXVHIRUWKHILUVWKRXUV
SRVWRSZHSODQWRLQFOXGHDOOQDUFRWLFXVDJHLQWKLVWLPHSHULRGDVWKHSULPDU\RXWFRPH
RI WKH SURSRVHG VWXG\  7KH HVWLPDWHG GLIIHUHQFH EHWZHHQ WKH JURXSV DW  KRXUV
SURGXFHGDQHIIHFWVL]HRIG 7KLVHIIHFWVL]HZRXOGRQO\UHTXLUHDVDPSOHVL]HRI
LQHDFKJURXSWRDFKLHYHDSRZHURIWRGHWHFWDVWDWLVWLFDOO\VLJQLILFDQWGLIIHUHQFH
IRUDOSKD *LYHQWKHDWWULWLRQLQWKH3DUDVFRQGRODVWXG\LWZRXOGVHHPDGYLVDEOHWR
YLHZ WKLV HIIHFW VL]H DV KDYLQJ D FHUWDLQ GHJUHH RI XQUHOLDELOLW\ DVVRFLDWHG ZLWK LW
7KHUHIRUHZHDOVRH[DPLQHGWKHPDJQLWXGHRIWKHGLIIHUHQFHLQWUHDWPHQWJURXSVZKLFK
ZDVREVHUYHGDWWKHKRXUWLPHSRLQWG 8VLQJWKHPLGSRLQWRIG 
VXEMHFWVSHUJURXSZRXOGEHUHTXLUHGWRKDYHVWDWLVWLFDOSRZHU IRUDOSKD (YHQ
LI WKH XQGHUO\LQJ HIIHFW VL]H ZHUH G  D VDPSOH VL]H RI  SHU JURXS ZRXOG KDYH
SRZHU  ZLWK DOSKD   7KLV VDPSOH VL]H Q JURXS VKRXOG DOVR SURYLGH
UHDVRQDEOHSRZHUWRGHWHFWVLJQLILFDQWGLIIHUHQFHVIRUWKHVHFRQGDU\RXWFRPHVRISDLQ
DVVHVVPHQWDWDQGKRXUVDVZHOODVWKHFXPXODWLYHSDLQVFRUHDWKRXUV
DUHDXQGHUWKHFXUYH$8&6DPSOHVL]HGHWHUPLQDWLRQZDVPDGHXVLQJ*3RZHU
)DXO)(UGIHOGHU(%XFKQHU$	/DQJ$*6WDWLVWLFDOSRZHU
DQDO\VHVXVLQJ*3RZHU7HVWVIRUFRUUHODWLRQDQGUHJUHVVLRQDQDO\VHV%HKDYLRU
5HVHDUFK0HWKRGV
6WDWLVWLFDO0HWKRGV
'HVFULSWLYH VWDWLVWLFV LQFOXGLQJ PHDQV VWDQGDUG GHYLDWLRQV PHGLDQV LQWHUTXDUWLOH
UDQJHV ± ,45V DQG IUHTXHQFLHV FRXQWV  SHUFHQWDJHV ZLOO EH XVHG WR SUHVHQW WKH
EDVHOLQHFKDUDFWHULVWLFVIRUWKHJURXSV,QGHSHQGHQWJURXS¶VWWHVWV:LOFR[RQUDQN
Oct
,5%180%(5
,5%$33529$/'$7(


14
Version 1.5
October 27, 2020
VXPWHVWVDQGFKLVTXDUHGWHVWVRILQGHSHQGHQFHRUH[DFWWHVWVDVDSSURSULDWHZLOOEH
XVHG WR FRPSDUH EDVHOLQH FKDUDFWHULVWLFV RI WKH  JURXSV WR DVVHVV HIIHFWLYHQHVV RI
UDQGRPL]DWLRQ:LOFR[RQUDQNVXPWHVWVZLOODOVREHXVHGWRWHVWIRUGLIIHUHQFHVEHWZHHQ
WKHJURXSVRQWKHSULPDU\RXWFRPHPHDVXUHFXPXODWLYHQDUFRWLFXVHRYHUWKHILUVW
KRXUVSRVWRSDVZHOODVVHFRQGDU\RXWFRPHVLQFOXGLQJSDLQVFRUHVOHQJWKRIVWD\DQG
FRVW&KLVTXDUHGWHVWVRU)LVKHU¶VH[DFWWHVWVZLOOEHXVHGWRFRPSDUHWKHSURSRUWLRQV
RI SDWLHQWV LQ WKH  JURXSV H[SHULHQFLQJ FRPSOLFDWLRQV RU XVLQJ RSLRLGV DW  DQG 
PRQWKV
 '$7$0$1$*(0(17$1'&21),'(17,$/,7<
6WXG\FRRUGLQDWRUVZLOOEHUHVSRQVLEOHIRUGDWDFROOHFWLRQDQGZLOOHQVXUHWKDWIRUPVDUH
FRPSOHWHGDQGVLJQHG3URWHFWHG+HDOWK,QIRUPDWLRQ3+,ZLOOEHUHFRUGHGIRUWUDFNLQJ
WKHVXEMHFWVWKURXJKWKHFRXUVHRIWKHVWXG\6XEMHFWVPD\EHDVVLJQHG,'VIRUXQELDVHG
DQDO\VLVKRZHYHUWKHVH,'VZLOOEHOLQNHGWR3+,VHSDUDWHO\'DWDZLOOEHFROOHFWHGRQ
GDWDFROOHFWLRQIRUPVDSSHQGL[LQFOXGLQJ$(DQGPHGLFDWLRQORJVDQGVXEVHTXHQWO\
HQWHUHG LQWR 5HG&$3 IRU VWDWLVWLFDO DQDO\VLV  2ULJLQDO VLJQHG FRQVHQW IRUPV GDWD
FROOHFWLRQ IRUPV DQG DQ\ UHOHYDQW VRXUFH GRFXPHQWDWLRQ ZLOO EH PDLQWDLQHG IRU WKH
GXUDWLRQRIWKHVWXG\LQORFNHGILOHFDELQHWVLQVLGH&DUGLRWKRUDFLF6XUJHU\RIILFHVXLWHV
(OHFWURQLF GDWD ZLOO EH VWRUHG RQ D VHFXUH VHUYHU DFFHVVLEOH YLD SDVVZRUGSURWHFWHG
FRPSXWHU2QO\DXWKRUL]HGVWXG\SHUVRQQHOZLOOKDYHDFFHVVWRWKHVWXG\GDWD$IWHU
FRPSOHWLRQRIGDWDDQDO\VLVDQGILQDOPDQXVFULSWVDSSURYDODOOQRQHOHFWURQLFUHFRUGV
ZLOOEHVHQWWR6,85HFRUGV0DQDJHPHQWIRUH[WHQGHGVWRUDJH5HFRUGVZLOOEHVWRUHGIRU
VXFKDSHULRGDIWHUVWXG\FRPSOHWLRQDVGLFWDWHGE\6,8UHJXODWLRQV
 $66(66(0(172)6$)(7<
6WRSSLQJUXOHVDQGDWWULEXWHVRIVHULRXVQHVVXQH[SHFWHGQHVVVHYHULW\DQGFDXVDOLW\ZLOO
EHDVVLJQHGE\WKHLQYHVWLJDWRUVDQGIXUWKHUUHYLHZHGGXULQJPRQWKO\PHHWLQJVRUDV
QHHGHGEDVHGRQXUJHQF\DVSDUWRIWKHGDWDDQGVDIHW\PRQLWRULQJSODQ'603
6XPPDU\6FUHHQLQJHOLJLELOLW\ZLOOEHUHYLHZHGEDVHGRQVWDQGDUGRIFDUHWHVWLQJGRQH
IRUWKHHOHFWLYHLQGH[SURFHGXUH$GYHUVHHYHQWV$(ZLOOEHPRQLWRUHGDQGUHFRUGHG
GDLO\WKURXJKRXWWKHVXEMHFWV¶KRVSLWDOVWD\DQGDJDLQDWWKHLUSRVWVXUJLFDOIROORZXSYLVLWV
GD\DQGDWPRQWKDQG\HDUSDUWRIVWDQGDUGRIFDUHHLWKHULQSHUVRQRUWKURXJK
UHYLHZRIVXEMHFWV¶(+5VDQGSKRQHLQWHUYLHZV7KHVHZLOOEHUHYLHZHGLQGLYLGXDOO\E\
WKH3,DQGFRLQYHVWLJDWRUVDQGUHSRUWHGE\VWXG\SHUVRQQHO$QDGYHUVHHYHQWORJZLOOEH
FUHDWHGIRUWKLVVWXG\5HJXODUO\VFKHGXOHGPHHWLQJVRIVWXG\SHUVRQQHOZLOOWDNHSODFHWR
UHYLHZ VWXG\ SURJUHVV SURFHGXUHV $(V DQG VDIHW\ FRQVLGHUDWLRQV 5HDO WLPH
PDQDJHPHQW RI $(V ZLOO EH GRQH SHU VWDQGDUG RI FDUH E\ WKH VXEMHFWV¶ KHDOWK FDUH
SURYLGHUV$Q\VHULRXV$(RUXQDQWLFLSDWHGSUREOHPVZLOOEHUHSRUWHGWRWKH6SULQJILHOG
Oct
,5%180%(5
,5%$33529$/'$7(


15
Version 1.5
October 27, 2020
&RPPLWWHH IRU 5HVHDUFK ,QYROYLQJ +XPDQ 6XEMHFWV 6&5,+6 LQ DFFRUGDQFH ZLWK
6&5,+6SROLF\
6SHFLILFDWLRQRI6DIHW\3DUDPHWHUV6DIHW\RIH[SDUHODQGPDUFDLQHZLOOEHHYDOXDWHGLQ
WKLVVWXG\6DIHW\HQGSRLQWVZLOOLQFOXGH
 $GYHUVHHYHQWVLQFOXGLQJVHULRXVDGYHUVHHYHQWV6$(VVXVSHFWHG$'5V
DQGGLVFRQWLQXDWLRQVGXHWR$(V
 3K\VLFDOH[DPLQDWLRQ
 9LWDOVLJQV
Oct
,5%180%(5
,5%$33529$/'$7(


16
Version 1.5
October 27, 2020
Table 1: Schedule of study assessments
$VVHVVPHQW
%DVHOLQH
6FUHHQLQJ
3UHRS
'
23
'
(DFK
32'
KRVSLWDO
GLVFKDUJH
)83
'G
)83
P
)83
P
,QFOXVLRQH[FOXVLRQ
;
;
,&)
;
9LWDOV
;
;
;
;
;
;
;
3(GRQHDVVWDQGDUG
RIFDUHE\DQ\
DXWKRUL]HGFOLQLFDOWHDP
PHPEHU
;
;
;
;
;
;
;
0HGLFDO6XUJLFDO
+LVWRU\
;
&RQFRPLWDQW
PHGLFDWLRQVH[FOXGLQJ
SDLQ5[
;
;
;
;
;
;
;
;
3DLQRSLRLGPHGLFDWLRQ
ORJ
;
;
;
;
;
;
;
;
5DQGRPL]DWLRQ
;
6WXG\GUXJ
DGPLQLVWUDWLRQ
;
3DLQ9$6
;
;
;
;
;
;
;
,QFHQWLYHVSLURPHWU\
GRQHDWEHGVLGH
;
;
;
0(4
;
;
;
;
;
;
&RPSOLFDWLRQV
;
;
;
;
;
;
2Q 32' DQG ODWHU SDLQ DVVHVVPHQW ZLOO EH GRQH DV LV VWDQGDUG RI FDUH E\
KRVSLWDOVWDIIXQWLOGLVFKDUJH
&DOFXODWLRQRI0(4XVLQJKWWSFOLQFDOFFRP2SLRLGV
Oct
,5%180%(5
,5%$33529$/'$7(


17
Version 1.5
October 27, 2020
5HIHUHQFHV
•
5XGG5$6HWK3'DYLG)6FKROO/,QFUHDVHVLQ'UXJDQG2SLRLG,QYROYHG
2YHUGRVH'HDWKV²8QLWHG6WDWHV±00:50RUE0RUWDO:NO\5HS
±'2,KWWSG[GRLRUJPPZUPPH
•
+XJKHV5*DR)3DLQ&RQWUROIRU7KRUDFRWRP\Continuing Education 
in Anaesthesia, Critical Care, & Pain. 5
•
.KDOLO.*%RXWURXV0/,UDQL$'0LOOHU&&3DZHOHN75(VWUHUD$
/6DIL+-2SHUDWLYH,QWHUFRVWDO1HUYH%ORFNVZLWK/RQJ$FWLYH
%XSLYDYLQHIRU3DLQ&RQWURODIWHU7KRUDFRWRP\The Annals of Thoracic Surgery. 
100, 2013-2018.
•
7D\ORU50DVVH\63RVWRSHUDWLYH$QDOJHVLDLQ9LGHR$VVLVWHG
7KRUDFRVFRS\7KH5ROHRI,QWHUFRVWDO%ORFNDGHJournal of Cardiothoracic and 
Vascular Analgesia. 18
•
7KH&RPPXQLW\%HKDYLRUDO+HDOWKFDUH$VVRFLDWLRQRI,OOLQRLV³The 
prescription Drug and Heroin Epidemic in Southern Illinois: A call for community 
health solutions”. 
•
8QLWHG6WDWHV:KLWH+RXVH&RXQFLORI(FRQRPLF$GYLVRUVThe 
Underestimated Cost of the Opioid Crisis
•
([SDUHO>SUHVFULELQJLQIRUPDWLRQ@3DUVLSDQ\1-3DFLUD3KDUPDFHXWLFDOV
,QF
•
0DUFDLQH>SUHVFULELQJLQIRUPDWLRQ@6DLQW/DXUHQW4XHEHF+RVSLUD
+HDOWKFDUH&RUSRUDWLRQ
•
.ROHWWDV$OH[DQGURVHWDO³3RVWRSHUDWLYH3DLQ0DQDJHPHQW´-RXUQDORI
7KRUDFLF'LVHDVH6XSSO6±630&:HE1RY
•
$OIRQVR)LRUHOOLEfficacy of wound analgesia for controlling post-
thoracotomy pain: a randomized double-blind study.
•
*UDQW*-%DUHQKRO]<%RORWLQ(0%DQVLQDWK07XUQGRUI+3LVNRXQ
%'DYLGVRQ(0$1RYHO/LSRVRPDO%XSLYDFDLQH)RUPXODWLRQWR
3URGXFH8OWUDORQJ$FWLQJ$QDOJHVLD.Anethesiology. 101. 133-137.
•
7D\ORU50DVVH\66WXDUW6PLWK.3RVWRSHUDWLYH$QDOJHVLDLQ9LGHR
$VVLVWHG7KRUDFRVFRS\WKHUROHRILQWHUFRVWDOORFNDGHJournal of Cardiothoracic 
and Vascular Anesthesia. 
•
'XDOH&*XDVWHOOD90RUDQG'&DUGRW-$XEOHW&XYHOLHU%0XOOLH]$
6FKRHIIOHU3(VFDQGH*'XEUD\&&KDUDFWHULVWLFVRIWKH1HXURSDWK\
,QGXFHGE\7KRUDFRWRP\DPRQWKIROORZXSVWXG\ZLWKSV\FKRSK\VLFDO
H[DPLQDWLRQClinical Journal of Pain. 6). 471-480.
•
+HWPDQQ).RQJVJDDUG86DQGYLN/6KRX%UHGDO,3RVW
WKRUDFRWRP\3DLQ6\QGRPHDQG6HQVRU\'LVWXUEDQFHV)ROORZLQJ7KRUDFRWRP\
DWPRQWKDQGPRQWKIROORZXSVJournal of Pain Research. 
•
3DOLRXUDV'%DUEHWDNLV1/D]DULGLV*%DND60SRXNRYLQDV,
.DUDYDVLOLV9.LRXPLV,3LWVLRX*3DSDLZDQQRX$.DUDYHUJRX$
/DPSDNL6RILD.DWVLNRJLDQQLV10SDNDV$7VDNLULGLV..RUDQW]LV,
)DVVLDGLV1=DURJRXOLGLV.=DURJRXOLGLV39LGHRDVVLVWHG7KRUDFLF
Oct
,5%180%(5
,5%$33529$/'$7(


18
Version 1.5
October 27, 2020
6XUJHU\DQG3QHXPRWKRUD[5HYLHZDUWLFOHJournal of Thoracic Disease. 7(S1). 
56-61.
•
6RFLHW\RI7KRUDFLF6XUJHRQV*HQHUDO7KRUDFLF6XUJHU\'DWDEDVH([HFXWLYH
6XPPDU\
•
.ROHWWDV$OH[DQGURVHWDO³3RVWRSHUDWLYH3DLQ0DQDJHPHQW´-RXUQDORI
7KRUDFLF'LVHDVH6XSSO6±630&:HE1RY
•
+DPLOWRQ7$WKDQDVVRJOX97ULYHOOD06WULFNODQG/0HOORQ60XUUD\'
3DQGLW+/LSRVRPDO%XSLYDFDLQH3HULSKHUDO1HUYH%ORFNIRUWKH
0DQDJHPHQWRI3RVWRSHUDWLYH3DLQ5HYLHZCochrane Review, The Cochrane 
Collaboration. Published by John Wiley & Sons, Ltd.2016
•
)DXO)(UGIHOGHU(%XFKQHU$	/DQJ$*
3DUDVFRQGROD
Oct
,5%180%(5
,5%$33529$/'$7(